Market Intelligence, Clinical Progress, and High-Purity Reagents for PAH, Muscle Atrophy, Obesity, and Oncology.
Target Overview
ACVR2A (Activin A receptor type IIA, UniProt P27037) is a transmembrane serine/threonine kinase receptor of the TGF-β superfamily. It contains a protein kinase domain and mediates signaling of activins, myostatin, and GDF11. Key naturally occurring mutations include rs34917571, rs764255410 (found in gastric adenocarcinoma), and a somatic mutation in clear cell renal carcinoma (VAR_064692). These variants provide important tools for studying functional alterations in disease.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ACVR2A drug discovery.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ACVR2A ECD-Fc Fusion Protein. High purity (>95%), Endotoxin <1 EU/μg. Sequence Verified. HEK293 Expressed (Native Glycosylation). | View ACVR2A Products |
| Antigen (Mutant) | ACVR2A mutant proteins (e.g., rs34917571) for variant-specific studies. | View ACVR2A Products |
| Gene Delivery | ACVR2A Promise-ORF / Lentivirus. Full-length ORF for stable cell lines. Preserves conformational epitopes. | View ACVR2A Products |
| Benchmark Ab | Anti-ACVR2A Biosimilars (Sotatercept and Bimagrumab sequence references). Recombinant positive controls for ligand-trap and mAb assays. | View ACVR2A Products |
| Validator | ACVR2A siRNA Set. For knockdown verification and specificity controls. | View ACVR2A Products |
| Related Target A | ACVR2B (ActRIIB). High homology (>70% ECD similarity); critical for selectivity counter-screening. | View ACVR2B Products |
| Related Target B | MSTN (Myostatin) / GDF8. Primary ligand for muscle wasting and metabolic pathways. | View MSTN Products |
| Related Target C | ACVR1B (ALK4) / ACVR1 (ALK2). Type I co-receptors for activin/BMP signaling. | View ACVR1B Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Ligand selectivity & cross-reactivity (Activin A, Myostatin, GDF11, BMP9) | HEK293-expressed ACVR2A ECD-Fc with native glycosylation; multi-ligand binding kinetics via SPR/BLI. |
| Receptor isoform selectivity (ACVR2A vs ACVR2B) | Matched pair of ACVR2A and ACVR2B ECD proteins; strictly verified by mass spec (>95% purity). |
| Cross-species evaluation (human, cyno, mouse) | Ortholog proteins with sequence-verified glycosylation patterns; available for all three species. |
| Lack of positive controls for ligand-trap and mAb assays | Clinical benchmark biosimilars (Sotatercept class, Bimagrumab class) included. |
| False positives in cell-based assays | Validated ACVR2A siRNA and non-targeting controls for specificity checks, SMAD pathway verification. |
| High-concentration formulation stability | High-purity ECD protein for DSF/SLS aggregation studies. |
Live ACVR2A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The ACVR2A therapeutic field has entered a commercial validation phase following the FDA approval of sotatercept (Winrevair) for pulmonary arterial hypertension (PAH). Major players are now expanding into metabolic diseases: combination of ACVR2A/ACVR2B inhibitors (e.g., bimagrumab) with GLP-1 receptor agonists is emerging as a leading strategy to preserve muscle mass during weight loss. Meanwhile, next-generation Fc-fusions with refined selectivity profiles, bispecific antibodies targeting multiple TGF-β ligands, and high-concentration subcutaneous formulations are in active development. Additional frontiers include oncology (cachexia, solid tumors) and fibrosis. The field is shifting from first-generation ligand traps to more selective modalities that fine-tune receptor signaling to avoid vascular and reproductive side effects.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Fc-Fusion (Ligand Trap) | Merck (Acceleron), Keros Therapeutics | PAH, MDS/MPN Anemia | Multi-ligand binding kinetics; need high-purity ECD-Fc (>95%) |
| Monoclonal Antibody | Eli Lilly (Versanis), Novartis, Regeneron | Obesity, Sarcopenia, Cancer Cachexia | Isoform selectivity (ACVR2A vs ACVR2B); need homolog panel proteins |
| Bispecific / Multi-specific | Scholar Rock, Biogen | Cancer Cachexia, Fibrosis | Heterodimer validation; need cross-reactive Abs vs ACVR2A/ACVR2B |
| Small Molecule Kinase Inhibitor | Various Biotechs | Oncology, Fibrosis | Selectivity against related kinases; need purified kinase domain |
| Peptide Antagonists | Multiple Biotechs | Metabolic Disease | Affinity maturation; need high-quality ECD for SPR/BLI |